NEW PYRROLOPYRIMIDINE COMPOUND OR ITS SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT, IN PARTICULAR, AGENT FOR PREVENTION AND / OR TREATMENT OF TUMORS AND SO ON, BASED ON INHIBITING INFLUENCE ON NAE Russian patent published in 2018 - IPC C07D487/04 A61K31/519 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a novel compound or a pharmaceutically acceptable salt of Formula (A) having the properties of an NAE inhibitor (Neddβ activating enzyme). In the Formula (A)

is a single or double bond; X is -O- or -CH=; Y is -NH- or -O-; R₁ is a hydrogen atom or a hydroxy group; R₂ is a hydrogen atom or a hydroxy group; R₃ is an ethynylene group or a 5-membered monocyclic heteroarylene group containing one to two heteroatoms selected from the group consisting of N, S and O; R₄ is a bond, a methylene group or a C3-C7 cycloalkylidene group; R₅ is a C3-C7 saturated cycloalkyl group, a C6-C10 unsaturated cycloalkyl group selected from phenyl, naphthyl, indanyl, which may contain one or more groups R₆, or a 5-6 membered monocyclic or 9-10 membered bicyclic unsaturated heterocycloalkyl group, which contains one to three heteroatoms selected from the group consisting of N, S and O, and which may contain one or more groups R₆; R₆ is a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group, which may contain one phenoxy group as substituents, a carbamoyl group, a C1-C6 alkoxycarbonyl group, a 6-membered monocyclic or bicyclic unsaturated heterocycloalkyl group containing one heteroatom N, 4-6 membered monocyclic or 8-membered bicyclic saturated heterocycloalkyl group, which contains one to four heteroatoms selected from the group consisting of N, S and O, and which may contain one or more groups, or a halogen atom, a hydroxy group, a carboxyl group or a C1-C6 alkyl group as substituents, an amino group, a mono- or di-(C1-C4alkyl)amino group which may have one hydroxy group or a phenyl group as substituents, C1-C6 alkoxy group which may contain one or more groups selected from a halogen atom, C3-C7 saturated cycloalkyl group, or a 5-membered monocyclic unsaturated heterocycloalkyl group, containing one to three heteroatoms of N, a benzyloxy group which may contain one or more carbamoyl groups as substituents, a C1-C6alkylthio group, a C1-C6alkylsulfonyl group or an aminosulfonyl group when there are two or more groups R₆, R₆ of this set may be the same or different.

EFFECT: compounds can be used as antitumor agents.

9 cl, 3 dwg, 21 tbl, 143 ex